Home Cart Sign in  
Chemical Structure| 915942-22-2 Chemical Structure| 915942-22-2

Structure of Neratinib maleate
CAS No.: 915942-22-2

Chemical Structure| 915942-22-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively.

Synonyms: HKI-272 maleate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Neratinib maleate

CAS No. :915942-22-2
Formula : C34H33ClN6O7
M.W : 673.11
SMILES Code : O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/CN(C)C.O=C(O)/C=C\C(O)=O
Synonyms :
HKI-272 maleate
MDL No. :MFCD30607264
InChI Key :VXZCUHNJXSIJIM-MEBGWEOYSA-N
Pubchem ID :67307512

Safety of Neratinib maleate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Neratinib maleate

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Description
Neratinib (HKI-272) maleate is an orally administered, irreversible inhibitor with high selectivity for HER2 and EGFR, exhibiting IC50 values of 59 nM and 92 nM, respectively. This specificity underlines its potential therapeutic application in targeting certain cancers[1].

In Vitro:

Cell Line
Concentration Treated Time Description References
SKBR3 5 nM 1 hour To evaluate the effect of Neratinib on SKBR3 cells, results showed that Neratinib significantly inhibited HER2 signaling in SKBR3 cells. Breast Cancer Res. 2019 Aug 13;21(1):94.
PANC1 cells 100 nM 12 hours To evaluate the cytotoxic effect of Neratinib on PANC1 cells, results showed that Neratinib caused ~15–20% cell killing. Oncogene. 2019 Jul;38(30):5890-5904.
TBCP-1 300 nM 24 hours To evaluate the effect of Neratinib on TBCP-1 cells, results showed that Neratinib significantly inhibited TBCP-1 cell proliferation and induced ferroptosis. Breast Cancer Res. 2019 Aug 13;21(1):94.
MDA-MB-453 10 nM 24 hours Neratinib monotherapy significantly inhibited cell viability compared to control or trastuzumab, and its combination with trastuzumab was also the most potent combination. Br J Cancer. 2024 Jun;130(12):1990-2002.
MDA-MB-361 10 nM 24 hours Neratinib monotherapy significantly inhibited cell viability compared to control or trastuzumab, and its combination with trastuzumab was also the most potent combination. Br J Cancer. 2024 Jun;130(12):1990-2002.
BT-474 1 µM 24 hours To evaluate the effect of Neratinib on downstream signaling pathways. Results showed that Neratinib alone reduced phosphorylation levels of ERK1/2, Akt, and S6K. Clin Cancer Res. 2021 Mar 15;27(6):1681-1694.
SK-BR-3 1 µM 24 hours To evaluate the effect of Neratinib on downstream signaling pathways. Results showed that Neratinib alone reduced phosphorylation levels of ERK1/2, Akt, and S6K. Clin Cancer Res. 2021 Mar 15;27(6):1681-1694.
HCC1954 150 nM 24 hours To evaluate the effect of Neratinib and Dasatinib on intracellular signaling, results showed that Neratinib significantly inhibited EGFR phosphorylation Transl Oncol. 2024 Nov;49:102073.
HCC1954-N 150 nM 24 hours To evaluate the effect of Neratinib and Dasatinib on intracellular signaling, results showed that Neratinib significantly inhibited EGFR Y1068 phosphorylation Transl Oncol. 2024 Nov;49:102073.
HME2-BM cells 100 nM 4 weeks To evaluate the effect of Neratinib on the drug resistance of HME2-BM cells, results showed that HME2-BM cells were able to spontaneously develop resistance after prolonged Neratinib treatment. Mol Biomed. 2022 Jun 22;3(1):19.
Jurkat T cells 50 nM 6 hours To evaluate the effect of Neratinib on the expression of K-RAS, MST3, and MST4 in Jurkat T cells, results showed that Neratinib significantly reduced the expression of these proteins. Oncogene. 2019 Jul;38(30):5890-5904.
HL60 cells 50 nM 6 hours To evaluate the effect of Neratinib on the expression of K-RAS, MST3, and MST4 in HL60 cells, results showed that Neratinib significantly reduced the expression of these proteins. Oncogene. 2019 Jul;38(30):5890-5904.
T cell lymphoma cells 50 nM 6 hours Neratinib significantly reduced the total expression and phosphorylation of MST4. J Cell Physiol. 2020 Nov;235(11):7889-7899.
INS-1E cells 5 µM, 10 µM 72 hours Neratinib potently inhibited H2O2- and high glucose/palmitate-induced MST1 activation and apoptosis in β-cells Nat Commun. 2019 Nov 1;10(1):5015.
Human islet cells 10 µM, 25 µM 72 hours Neratinib significantly inhibited pro-inflammatory cytokine- and high glucose/palmitate-induced MST1 activation and caspase-3 activation Nat Commun. 2019 Nov 1;10(1):5015.
HME2 cells 1 µM 96 hours To evaluate the inhibitory effect of Neratinib on HER2 phosphorylation, results showed that Neratinib significantly inhibited HER2 phosphorylation and led to receptor degradation. Mol Biomed. 2022 Jun 22;3(1):19.
Pancreatic cancer cells 50 nM Neratinib exhibited lethality in pancreatic cancer cells, and its lethality was enhanced when combined with HDAC inhibitors. J Cell Physiol. 2020 Nov;235(11):7889-7899.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Patient-derived xenografts (PDXs) Oral 10 mg/kg Daily for the duration of the experiment To evaluate the effect of Neratinib in combination with other inhibitors on tumor growth in HER2+ PDX models. Results showed that the combination of Neratinib with palbociclib significantly reduced tumor volume and extended event-free survival in all five PDX models. Clin Cancer Res. 2021 Mar 15;27(6):1681-1694.
Mice HER2-positive breast cancer xenograft models Oral 20 mg/kg Once daily, 5 days/week To evaluate the therapeutic benefit of N+T and compare its efficacy to P+T using HER2+breast cancer xenograft models. The results showed that N+T was more effective than P+T in accelerating tumor regression and achieving complete response. NPJ Breast Cancer. 2021 May 27;7(1):63
NSG mice HER2+ breast cancer model Oral gavage 27 mg/kg Every other day, until tumors reached 1000 mm3 To evaluate the therapeutic effect of Neratinib on HER2+ breast cancer model, results showed that Neratinib significantly inhibited the growth of HME2 parental tumors, but had a smaller effect on the growth of HME2-BM tumors, and overexpression of TG2 diminished the effectiveness of Neratinib. Mol Biomed. 2022 Jun 22;3(1):19.
Mice CW2 xenograft model Oral gavage 40 mg/kg Once daily for 14 days To study the effect of combined neratinib and alpelisib on tumor growth in CW2 xenograft models. Cancer Cell. 2021 Aug 9;39(8):1099-1114.e8
Mice STZ-induced type 1 diabetes model and obese Leprdb/db diabetes model Intraperitoneal injection 5 mg/kg Daily for 35 days (STZ model) or 31 days (db/db model) Neratinib significantly attenuated hyperglycemia and restored β-cell function, survival, and β-cell mass Nat Commun. 2019 Nov 1;10(1):5015.
Female Albino Wistar rats Neratinib-induced diarrhea model Oral 50 mg/kg Once daily for 28 days To investigate the impact of antibiotics on neratinib-induced diarrhea. Results showed that vancomycin or neomycin significantly reduced diarrhea levels, while the broad-spectrum antibiotic cocktail was less effective. Neoplasia. 2022 Aug;30:100806
BALB/C mice HER2-positive breast cancer brain metastasis model Oral gavage 60 mg/kg Once daily for 3 weeks To evaluate the efficacy of Neratinib in a preventive neoadjuvant setting, results showed that Neratinib significantly prolonged survival and reduced the incidence of brain metastases. Breast Cancer Res. 2019 Aug 13;21(1):94.
BALB/c Nude mice HCC1954 xenograft model Oral Neratinib 10 mg/kg, Dasatinib 15 mg/kg 5 days on, 2 days off for 10 weeks To evaluate the anti-tumor effect of Neratinib and Dasatinib in vivo on HCC1954 xenograft model, results showed that the combination significantly inhibited tumor growth Transl Oncol. 2024 Nov;49:102073.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.49mL

0.30mL

0.15mL

7.43mL

1.49mL

0.74mL

14.86mL

2.97mL

1.49mL

References

 

Historical Records

Categories